Literature DB >> 24740136

Management options in locally advanced pancreatic cancer.

Omar Y Mian1, Ashwin N Ram, Richard Tuli, Joseph M Herman.   

Abstract

Pancreatic ductal adenocarcinoma is a highly lethal cancer that is rarely curable at the time of presentation. Unfortunately, most patients are diagnosed with either metastatic or locally advanced disease, which is not amenable to surgery owing to the high likelihood of incomplete resection. Given the generally poor prognosis with propensity for metastatic failure greater than that for local failure, treatment options are variable, and include chemotherapy, radiotherapy, targeted therapies, and combinations thereof. This review summarizes the current evidence for definitive management of locally advanced pancreatic adenocarcinoma, as well as the role of palliative therapies. Future directions, including the development of predictive biomarkers and novel systemic agents, are also discussed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24740136     DOI: 10.1007/s11912-014-0388-y

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  91 in total

1.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

Review 2.  Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.

Authors:  Matthew H G Katz; Robert Marsh; Joseph M Herman; Qian Shi; Eric Collison; Alan P Venook; Hedy L Kindler; Steven R Alberts; Philip Philip; Andrew M Lowy; Peter W T Pisters; Mitchell C Posner; Jordan D Berlin; Syed A Ahmad
Journal:  Ann Surg Oncol       Date:  2013-02-23       Impact factor: 5.344

3.  Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery.

Authors:  Timothy R Donahue; William H Isacoff; O Joe Hines; James S Tomlinson; James J Farrell; Yasser M Bhat; Edward Garon; Barbara Clerkin; Howard A Reber
Journal:  Arch Surg       Date:  2011-07

4.  Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.

Authors:  K A Bickenbach; M Gonen; Laura H Tang; Eileen O'Reilly; Karyn Goodman; M F Brennan; M I D'Angelica; R P Dematteo; Y Fong; W R Jarnagin; P J Allen
Journal:  Ann Surg Oncol       Date:  2011-12-01       Impact factor: 5.344

5.  Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.

Authors:  Jerome Landry; Paul J Catalano; Charles Staley; Wayne Harris; John Hoffman; Mark Talamonti; Natalie Xu; Harry Cooper; Al B Benson
Journal:  J Surg Oncol       Date:  2010-06-01       Impact factor: 3.454

6.  A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.

Authors:  Edgar Ben-Josef; Mathew Schipper; Isaac R Francis; Scott Hadley; Randall Ten-Haken; Theodore Lawrence; Daniel Normolle; Diane M Simeone; Christopher Sonnenday; Ross Abrams; William Leslie; Gazala Khan; Mark M Zalupski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-27       Impact factor: 7.038

7.  Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas.

Authors:  R R White; H I Hurwitz; M A Morse; C Lee; M S Anscher; E K Paulson; M R Gottfried; J Baillie; M S Branch; P S Jowell; K M McGrath; B M Clary; T N Pappas; D S Tyler
Journal:  Ann Surg Oncol       Date:  2001-12       Impact factor: 5.344

8.  18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy.

Authors:  Devin Schellenberg; Andy Quon; A Yuriko Minn; Edward E Graves; Pamela Kunz; James M Ford; George A Fisher; Karyn A Goodman; Albert C Koong; Daniel T Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-07       Impact factor: 7.038

9.  Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

Authors:  Jordan D Berlin; Paul Catalano; James P Thomas; John W Kugler; Daniel G Haller; Al Bowen Benson
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

10.  Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

Authors:  Caio M Rocha Lima; Mark R Green; Robert Rotche; Wilson H Miller; G Mark Jeffrey; Laura A Cisar; Adele Morganti; Nicoletta Orlando; Gabriela Gruia; Langdon L Miller
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

View more
  20 in total

1.  Shear Wave Elastography Can Differentiate between Radiation-Responsive and Non-responsive Pancreatic Tumors: An ex Vivo Study with Murine Models.

Authors:  Hexuan Wang; Bradley Mills; Reem Mislati; Rifat Ahmed; Scott A Gerber; David Linehan; Marvin M Doyley
Journal:  Ultrasound Med Biol       Date:  2019-11-11       Impact factor: 2.998

2.  Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma.

Authors:  James D Byrne; Mohammad R N Jajja; Allison N Schorzman; Amanda W Keeler; J Christopher Luft; William C Zamboni; Joseph M DeSimone; Jen Jen Yeh
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

3.  Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients.

Authors:  Yong Yue; Arsen Osipov; Benedick Fraass; Howard Sandler; Xiao Zhang; Nicholas Nissen; Andrew Hendifar; Richard Tuli
Journal:  J Gastrointest Oncol       Date:  2017-02

4.  Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer.

Authors:  Moumita Chatterjee; Edgar Ben-Josef; Dafydd G Thomas; Meredith A Morgan; Mark M Zalupski; Gazala Khan; Charles Andrew Robinson; Kent A Griffith; Ching-Shih Chen; Thomas Ludwig; Tanios Bekaii-Saab; Arnab Chakravarti; Terence M Williams
Journal:  Sci Rep       Date:  2015-06-12       Impact factor: 4.379

Review 5.  Chinese Herbal Medicines as an Adjunctive Therapy for Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.

Authors:  Bin Li; Run Gan; Quanjun Yang; Jinlu Huang; Pengguo Chen; Lili Wan; Cheng Guo
Journal:  Evid Based Complement Alternat Med       Date:  2015-11-23       Impact factor: 2.629

6.  RGS16, a novel p53 and pRb cross-talk candidate inhibits migration and invasion of pancreatic cancer cells.

Authors:  Miranda B Carper; James Denvir; Goran Boskovic; Donald A Primerano; Pier Paolo Claudio
Journal:  Genes Cancer       Date:  2014-11

7.  ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer.

Authors:  T Watanabe; H Ueno; Y Watabe; N Hiraoka; C Morizane; J Itami; T Okusaka; N Miura; T Kakizaki; T Kakuya; M Kamita; A Tsuchida; Y Nagakawa; H Wilber; T Yamada; K Honda
Journal:  Br J Cancer       Date:  2015-01-20       Impact factor: 7.640

8.  The biological role of actinin-4 (ACTN4) in malignant phenotypes of cancer.

Authors:  Kazufumi Honda
Journal:  Cell Biosci       Date:  2015-08-18       Impact factor: 7.133

9.  Impact of Comorbidity and Age on Determinants Therapeutic Strategies in Advanced Pancreatic Head Cancer Patients With Obstructive Jaundices.

Authors:  Yu-Guang Chen; Hsueh-Hsing Pan; Ming-Shen Dai; Chin Lin; Chieh-Sheng Lu; Sui-Lung Su; Ping-Ying Chang; Tzu-Chuan Huang; Jia-Hong Chen; Yi-Ying Wu; Yeu-Chin Chen; Ching Liang Ho
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.889

10.  Mesenchymal stem cells promote pancreatic adenocarcinoma cells invasion by transforming growth factor-β1 induced epithelial-mesenchymal transition.

Authors:  Hai-Sen Zhou; Xiao-Fang Su; Xing-Li Fu; Guo-Zhong Wu; Kun-Lun Luo; Zheng Fang; Feng Yu; Hong Liu; Hong-Juan Hu; Liu-Sheng Chen; Bing Cai; Zhi-Qiang Tian
Journal:  Oncotarget       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.